Crossmark

Efficacy and Safety of TACE Combined with a Tyrosine Kinase Inhibitor for the Treatment of TACE-Refractory Hepatocellular Carcinoma: A Retrospective Comparative Study

Crossref DOI link: https://doi.org/10.1007/s12029-024-01036-4

Published Online: 2024-03-12

Published Print: 2024-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chen, Yu-Xing

Zhang, Jin-Xing

Zhou, Chun-Gao

Liu, Jin

Liu, Sheng

Shi, Hai-Bin

Zu, Qing-Quan

Cheng, Yuan
Funding

Funding for this research was provided by:

Interventional Medicine Research Fund of Jiangsu Medical Association (SYH-3201140-0049)

Jiangsu Province Capability Improvement Project through Science, Technology and Education (JSDW202243)
License Information

Text and Data Mining valid from 2024-03-12

Version of Record valid from 2024-03-12
More Information

Article History

Accepted: 2 March 2024

First Online: 12 March 2024

Declarations

:

: The authors declare no competing interests.

Document is current

Any future updates will be listed below